Search for a command to run...
Centene Corporation
Healthcare Plans
| Date | Politician | Asset | Action | Amount | Trade Price | 30D Price | 1M Return | Alpha | 1M Prediction |
|---|---|---|---|---|---|---|---|---|---|
May 15, 2026 |  Rohit KhannaD | Stock | Buy |
| $1,001 - $15,000 |
| $58.27 |
| $65.19 |
| +11.9% |
| +11.5% |
Feb 5, 2026 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $39.92 | $43.65 | +9.3% | +10.1% |
Jan 29, 2026 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $43.60 | $44.88 | +2.9% | +4.1% |
Aug 18, 2025 |  Tim MooreR | Stock | Sell | $100,001 - $250,000 | $28.99 | $32.02 | +10.5% | +8.0% |
Aug 8, 2025 |  Julia LetlowR | Stock | Sell | $1,001 - $15,000 | $25.59 | $28.98 | +13.2% | +11.7% |
Aug 8, 2025 | Tim MooreR | Stock | Buy | $1,001 - $15,000 | $25.59 | $28.98 | +13.2% | +11.7% |
Aug 7, 2025 | Tim MooreR | Stock | Buy | $15,001 - $50,000 | $25.26 | $28.98 | +14.7% | +12.4% |
Aug 5, 2025 |  Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $25.89 | $28.65 | +10.7% | +7.3% |
Aug 4, 2025 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $26.21 | $30.06 | +14.7% | +12.7% |
Jul 30, 2025 | Tim MooreR | Stock | Buy | $15,001 - $50,000 | $25.79 | $29.04 | +12.6% | +10.9% |
Jul 29, 2025 | Tim MooreR | Stock | Buy | $15,001 - $50,000 | $25.53 | $28.38 | +11.2% | +9.0% |
Jul 25, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $28.39 | $29.41 | +3.6% | +2.3% |
Jul 22, 2025 | Tim MooreR | Stock | Buy | $1,001 - $15,000 | $27.89 | $28.81 | +3.3% | +2.2% |
Jul 21, 2025 | Tim MooreR | Stock | Buy | $15,001 - $50,000 | $27.43 | $29.40 | +7.2% | +5.7% |
Jul 18, 2025 | Tim MooreR | Stock | Buy | $15,001 - $50,000 | $27.95 | $28.49 | +1.9% | -0.6% |
Jul 14, 2025 | Tim MooreR | Stock | Buy | $15,001 - $50,000 | $30.64 | $27.07 | -11.7% | -14.9% |
Jun 23, 2025 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $53.40 | $29.42 | -44.9% | -50.6% |
Jun 20, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $54.40 | $27.95 | -48.6% | -54.2% |
Jun 20, 2025 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $54.40 | $27.95 | -48.6% | -54.2% |
May 30, 2025 | Gilbert CisnerosD | Stock | Sell | $1,001 - $15,000 | $56.44 | $53.99 | -4.3% | -9.0% |
May 28, 2025 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $55.93 | $53.99 | -3.5% | -8.4% |
May 19, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $61.55 | $55.15 | -10.4% | -10.8% |
May 15, 2025 |  Rob BresnahanR | Stock | Sell | $1,001 - $15,000 | $60.06 | $55.22 | -8.1% | -9.2% |
May 12, 2025 |  Jefferson ShreveR | Stock | Sell | $15,001 - $50,000 | $62.87 | $55.27 | -12.1% | -15.2% |
Apr 29, 2025 | Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $59.26 | $56.52 | -4.6% | -11.1% |
Apr 23, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $62.12 | $56.41 | -9.2% | -17.4% |
Apr 14, 2025 | Julia LetlowR | Stock | Buy | $1,001 - $15,000 | $63.01 | $59.47 | -5.6% | -14.6% |
Apr 8, 2025 | Rob BresnahanR | Stock | Buy | $1,001 - $15,000 | $62.40 | $62.42 | +0.0% | -13.8% |
Mar 31, 2025 | Gilbert CisnerosD | Stock | Sell | $1,001 - $15,000 | $60.71 | $59.85 | -1.4% | -0.5% |
Mar 12, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $58.45 | $63.86 | +9.3% | +13.4% |
Mar 5, 2025 | Jefferson ShreveR | Stock | Buy | $15,001 - $50,000 | $59.00 | $61.93 | +5.0% | +18.0% |
Feb 25, 2025 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $61.33 | $60.23 | -1.8% | +2.5% |
Feb 19, 2025 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $57.66 | $58.90 | +2.2% | +9.9% |
Jan 17, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $62.25 | $56.86 | -8.7% | -10.7% |
Dec 18, 2024 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $59.49 | $62.25 | +4.6% | +2.4% |
Dec 16, 2024 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $59.17 | $63.15 | +6.7% | +8.7% |
Oct 29, 2024 |  Valerie HoyleD | Stock | Buy | $1,001 - $15,000 | $60.62 | $59.93 | -1.1% | -4.1% |
This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday
UBS Maintains Neutral on Centene, Raises Price Target to $61
This Q32 Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
Centene, Molina Have 'Compelling' EPS Upside Potential as Medicaid Margins Likely Improve 2027 Onwards, BofA Says
B of A Securities Maintains Buy on Centene, Raises Price Target to $72